Last reviewed · How we verify
Teflaro (CEFTAROLINE FOSAMIL)
Teflaro works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Ceftaroline fosamil (Teflaro), marketed by AbbVie, is an established antibiotic primarily indicated for treating bacterial infections caused by Klebsiella pneumoniae. A key strength of Teflaro is its mechanism of action, which effectively inhibits bacterial cell wall synthesis, leading to bacterial cell death. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | CEFTAROLINE FOSAMIL |
|---|---|
| Sponsor | AbbVie |
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2010 |
Mechanism of action
Ceftaroline is cephalosporin antibacterial drug see Microbiology 12.4 )].
Approved indications
- Bacterial infection due to Klebsiella pneumoniae
- Haemophilus influenzae pneumonia
- Infection due to Escherichia coli
- Infection due to Staphylococcus aureus
- Pneumococcal pneumonia
- Pneumonia due to Escherichia coli
- Pneumonia due to Staphylococcus aureus
- Rhinoscleroma
- Skin and Skin Structure Streptococcus Agalactiae Infection
- Streptococcus pyogenes infection
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Pyrexia
- Constipation
- Hypokalemia
- Phlebitis
- Increased transaminases
- Anemia
- Eosinophilia
- Neutropenia
Key clinical trials
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
- Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teflaro CI brief — competitive landscape report
- Teflaro updates RSS · CI watch RSS
- AbbVie portfolio CI